Salute e Benessere

Sectra adds Smith+Nephew 3D templates to its orthopaedic solution--supporting…

"3D planning in orthopaedics is rapidly advancing and promises to play an important role in improving the efficiency and outcomes of trauma care. Sectra's integrated planning tools incorporating implant templates from leading brands like Smith+Nephew enhance our ability to prepare for complex procedures with precision and confidence." "3D planning in orthopaedics is rapidly advancing and promises to play an important role in improving the efficiency and outcomes of trauma…

Enterome receives FDA Fast Track designation in follicular lymphoma for lead…

Covers low tumor burden “watch-and-wait” setting, an unmet medical needRegistrational Phase 3 watch-and-wait to start in 2026EO2463 has broad potential to treat hemato-oncology indicationsParis, France – 16 OCTOBER, 2025 Enterome, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer,announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for follicular lymphoma in the low tumor burden...

The Board of Directors maintains its recommendation in supplementary statement…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, October 16, 2025– Reference is made to Bavarian Nordic A/S' ("Bavarian Nordic" or the "Company") announcements of 26 August 2025 (no. 24/2025 and no. 25/2025) regarding the publication of the offer document, as amended by the supplements dated 29 September 2025…

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney…

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years 1 eGFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients 1-3 Fabhalta is first and only approved complement inhibitor for adults with IgAN and has potential to delay disease progression 4,5 ...

Roche presents major advances for its sequencing by expansion technology(1)…

Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research previously out of reach for traditional short read platforms.Leveraging Roche’s SBX technology, Broad Clinical Labs achieved the new GUINNESS WORLD RECORD™ for fastest DNA sequencing technique in under four hours, in collaboration with Roche Sequencing Solutions and Boston Children’s Hospital.Wellcome Sanger Institute joins a growing network of early...

Kuros Biosciences increases the annual guidance for 2025, The company reports…

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases the annual guidance for 2025The company reports 77% year-over-year increase for the first nine months of 2025 Financial & Operational HighlightsTotal Medical Device sales rose by 77% to USD 101.1 million for the first nine months of 2025 (9M 2024: USD 57.2 million)Direct MagnetOs™ sales increased by 76% to USD 99.7 million for the first nine months of 2025 (9M 2024: USD 56...

Gastrointestinal Neuroendocrine Tumors Market Set to Surge by 2034 Amidst…

Gastrointestinal Neuroendocrine Tumors Market Summary Gastrointestinal Neuroendocrine Tumors Market Summary Discover the gastrointestinal neuroendocrine tumors new treatment @New Treatments for Gastrointestinal Neuroendocrine Tumors Key Factors Driving the Growth of the Gastrointestinal Neuroendocrine Tumors Market Rising GI-NET Incident Cases The total number of incident cases of GI-NETs in the US was nearly15,500 casesin 2024 and is projected to increase by 2034...

PENTAX Medical Announces Sale of C2 CryoBalloon™ Product Line to Merit Medical…

This strategic move allows PENTAX Medical to sharpen its focus on core endoscopic solutions while fostering deeper clinical partnerships. This strategic move allows PENTAX Medical to sharpen its focus on core endoscopic solutions while fostering deeper clinical partnerships. The C2 CryoBalloon™ has been part of PENTAX Medical's therapeutic portfolio since 2017, offering a minimally invasive option to treat patients suffering from Barrett's Esophagus and other gastrointestinal disorders...

Liposomal CBD Injection Technology (LPT-CBD) patent was allowed in Japan

This patent protects Innocan's LPT-CBD formulation designed for the sustained release of synthetic CBD into the bloodstream. The newly allowed patent is part of a broad international patent family currently under examination in multiple jurisdictions worldwide. It joins the company's granted patent in India, further strengthening Innocan global intellectual property portfolio and ensuring maximum protection and enforceability. With Japan being the world's third-largest pharmaceutical market…

OSE Immunotherapeutics Reports First Half 2025 Financial Results

OSE Immunotherapeutics Reports First Half 2025 Financial ResultsNANTES, France, October 15, 2025 – 7:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today reported its consolidated financial results for the first half of 2025.The half-year financial statements for 2025 were subject to a limited review by the Company’s statutory auditors and were approved by the Board of Directors on October 15, 2025. 2025 Half-Year Financial Results (IFRS)In million euros...

EssilorLuxottica acquires RetinAI, accelerating transformative AI and…

EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutionsParis, France (15 October 2025)– EssilorLuxottica announces the acquisition of Ikerian AG, a health technology company, operating under the RetinAI brand, specializing in AI and data management in eyecare. This move reinforces the Group’s med-tech journey, adding advanced software powered by machine learning and computer vision. These solutions streamline clinical, research and...

OXURION : Information on the Total Number of Voting Rights (Denominator)…

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1]. Leuven, BELGIUM – 15 October, 2025 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of…

IPSEN - Buy-back programme - Art 5 of MAR - Week 41 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from October 06th to October 10th 2025 Name of the issueIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1106/10/2025FR0010259150300...

Consortium consisting of Nordic Capital and Permira increases offer price and…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, October 15, 2025– With reference to the announcement of 26 August 2025 (no. 24/2025) regarding the publication of the offer document (the "Offer Document " ) concerning the all-cash voluntary recommended public takeover offer to acquire all of the issued and outstanding...

Photocure and Intelligent Scopes Corporation partner on development of AI for…

In the current development phase, Photocure and ISC are collaborating to develop an AI software which can support the physician in real-time during blue light cystoscopy, improving early-stage bladder cancer detection, diagnosis, and resection completeness. The initial testing results were based on approximately 200 blue light procedures with more than 80,000 images. These results support the benefits of AI enabled blue light cystoscopy by detecting high risk cancerous lesions earlier in the…

Global Licensed Entertainment and Character Merchandise Market Set to Reach…

Get Free Sample Report What are the key factors driving the growth of the Licensed Entertainment and Character Merchandise Market? Source from Valuates Reports : https://reports.valuates.com/market-reports/QYRE-Auto-36H18456/global-licensed-entertainment-and-character-merchandise?utm_source=Prnewswire&utm_medium=Referral TRENDS INFLUENCING THE GROWTH OF THE LICENSED ENTERTAINMENT AND CHARACTER MERCHANDISE MARKET: Apparel plays a vital role in driving the...

Alcoholic Hepatitis Treatment Market to Reach $772.7 Million by 2027 in the…

Request Sample of the Report on Alcoholic Hepatitis Treatment Market Forecast 2034 -https://www.alliedmarketresearch.com/request-sample/A234521 Request Sample of the Report on Alcoholic Hepatitis Treatment Market Forecast 2034 -https://www.alliedmarketresearch.com/request-sample/A234521 Market Introduction The alcoholic hepatitis treatment market focuses on therapies addressing inflammation of the liver caused by excessive alcohol intake. This condition ranges from mild to...

The Pilates & Yoga Studios Market to Reach $120.88 Billion by 2025 in the short…

Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/4310 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/4310 Market Introduction Rise in consumer awareness of health and wellbeing has led to an increase in demand for Pilates and yoga facilities in recent years. Both yoga and Pilates, which are renowned for their holistic advantages, have become quite popular as they enhance mental health,...

Life Science Logistics Market is expected to generate a revenue of USD 236.28…

The global Life Science Logistics Market plays a vital role in ensuring the safe and efficient transportation of sensitive pharmaceuticals, biologics, and medical devices. Growing R&D in biotechnology and the need for secure cold chain systems are boosting market demand worldwide. For a detailed analysis of industry trends and growth drivers, explore the full Life Science Logistics Market. Browse in-depth TOC 202 - Pages 126 – Tables 37 – Figures...

Dental Implant Market Valuation to Reach USD 8.4 Billion by 2033, Growing at a…

Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=243877 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=243877 202 – Pages 126 – Tables 37 – Figures Scope Of The Report Feed Antioxidants Market Overview 1. Market Growth and Forecast The Dental Implant Market has witnessed substantial growth in recent years, with its valuation reachingUSD 5.2 billionin 2024 and expected to surge toUSD 8...

Active Pharmaceutical Ingredients (API) Market worth $198.39 billion by 2030…

Browse in-depth TOC on "Active Pharmaceutical Ingredients (API) Market" Browse in-depth TOC on "Active Pharmaceutical Ingredients (API) Market" 692 - Tables 65 - Figures 533 - Pages By Potency,the global active pharmaceutical ingredients market is segmented by potency into two major segments: traditional APIs and highly potent APIs (HPAPI). Traditional API include low-potency, medium-potency, and potent APIs. Low-potency APIs form category I of the SafeBridge…

Advanced Instruments is Now Merged Under the Nova Biomedical Name: One Unified…

"Our shared values—innovation, customer focus, and dedication to quality—are the foundation of this merger," said Byron Selman, President & CEO of Nova Biomedical. "Operating under the Nova Biomedical name allows us to amplify our global presence and continue delivering gold-standard solutions to our customers." "Our shared values—innovation, customer focus, and dedication to quality—are the foundation of this merger," saidByron Selman, President & CEO of…

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape

The industry's focus on combination strategies and novel targets is yielding promising clinical results, with antibody-drug conjugates, metabolic inhibitors, and immune-activating platforms demonstrating enhanced efficacy when paired with complementary mechanisms[2]. Major pharmaceutical companies are investing heavily in radioligand therapy and precision medicine infrastructure, while emerging biotech firms leverage genetic screening to identify patient populations most likely to benefit from…

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- Eight new oncology approvals between July and September 2025 marked a pivotal quarter for cancer treatment[1], as cellular immunotherapy platforms continue redefining treatment paradigms for hematologic malignancies and expanding into solid tumors[2]. Recent innovations including CAR-NK cells, CAR-Treg cells, and in vivo CAR-T approaches are solving manufacturing challenges[3] while outpatient CAR-T centers now deliver advanced therapies that…

Altri Comunicati